Literature DB >> 26506088

Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy.

Eilidh Somers1,2, Robert D Lees1, Katie Hoban1, James N Sleigh3, Haiyan Zhou4, Francesco Muntoni4, Kevin Talbot3, Thomas H Gillingwater1,2, Simon H Parson5,2.   

Abstract

OBJECTIVE: Spinal muscular atrophy (SMA) is a major inherited cause of infant death worldwide. It results from mutations in a single, ubiquitously expressed gene (SMN1), with loss of lower motor neurons being the primary pathological signature. Systemic defects have also been reported in SMA patients and animal models. We investigated whether defects associated with the vasculature contribute to motor neuron pathology in SMA.
METHODS: Development and integrity of the capillary bed was examined in skeletal muscle and spinal cord of SMA mice, and muscle biopsies from SMA patients and controls, using quantitative morphometric approaches on immunohistochemically labeled tissue. Pimonidazole hydrochloride-based assays were used to identify functional hypoxia.
RESULTS: The capillary bed in muscle and spinal cord was normal in presymptomatic SMA mice (postnatal day 1), but failed to match subsequent postnatal development in control littermates. At mid- and late-symptomatic time points, the extent of the vascular architecture observed in two distinct mouse models of SMA was ∼50% of that observed in control animals. Skeletal muscle biopsies from human patients confirmed the presence of developmentally similar, significant vascular depletion in severe SMA. Hypovascularity in SMA mouse spinal cord was accompanied by significant functional hypoxia and defects in the blood-spinal cord barrier.
INTERPRETATION: Our results indicate that vascular defects are a major feature of severe forms of SMA, present in both mouse models and patients, resulting in functional hypoxia of motor neurons. Thus, abnormal vascular development and resulting hypoxia may contribute to the pathogenesis of SMA.
© 2016 American Neurological Association.

Entities:  

Mesh:

Year:  2016        PMID: 26506088     DOI: 10.1002/ana.24549

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

Review 1.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

Review 2.  Advances in modeling and treating spinal muscular atrophy.

Authors:  Meaghan Van Alstyne; Livio Pellizzoni
Journal:  Curr Opin Neurol       Date:  2016-10       Impact factor: 5.710

Review 3.  Spinal muscular atrophy.

Authors:  Eugenio Mercuri; Charlotte J Sumner; Francesco Muntoni; Basil T Darras; Richard S Finkel
Journal:  Nat Rev Dis Primers       Date:  2022-08-04       Impact factor: 65.038

4.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

Review 5.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

6.  Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy.

Authors:  Gillian K Maxwell; Eva Szunyogova; Hannah K Shorrock; Thomas H Gillingwater; Simon H Parson
Journal:  J Anat       Date:  2018-02-22       Impact factor: 2.610

Review 7.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

8.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 9.  Revisiting the role of mitochondria in spinal muscular atrophy.

Authors:  Rachel James; Helena Chaytow; Leire M Ledahawsky; Thomas H Gillingwater
Journal:  Cell Mol Life Sci       Date:  2021-04-05       Impact factor: 9.261

10.  Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.

Authors:  Kaitlyn M Kray; Vicki L McGovern; Deepti Chugh; W David Arnold; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2021-08-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.